3.03
0.11 (3.60%)
| Previous Close | 2.92 |
| Open | 2.99 |
| Volume | 130,427 |
| Avg. Volume (3M) | 1,270,601 |
| Market Cap | 327,744,352 |
| Price / Sales | 19.85 |
| Price / Book | 2.44 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Operating Margin (TTM) | -1,222.27% |
| Diluted EPS (TTM) | -1.59 |
| Quarterly Revenue Growth (YOY) | -39.30% |
| Total Debt/Equity (MRQ) | 1.72% |
| Current Ratio (MRQ) | 5.06 |
| Operating Cash Flow (TTM) | -12.32 M |
| Levered Free Cash Flow (TTM) | -52.41 M |
| Return on Assets (TTM) | -18.20% |
| Return on Equity (TTM) | -91.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Aclaris Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 4.0 |
| Average | 1.88 |
|
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.69% |
| % Held by Institutions | 88.24% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bml Capital Management, Llc | 30 Sep 2025 | 14,250,000 |
| Vivo Capital, Llc | 30 Sep 2025 | 8,888,888 |
| Rock Springs Capital Management Lp | 30 Sep 2025 | 4,609,309 |
| Decheng Capital Llc | 30 Sep 2025 | 4,041,736 |
| Palo Alto Investors Lp | 30 Sep 2025 | 1,566,840 |
| 52 Weeks Range | ||
| Median | 16.00 (428.93%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 20 Oct 2025 | 16.00 (428.93%) | Buy | 2.01 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| DAVIS HUGH M. | - | - | 0 | 0 |
| Aggregate Net Quantity | 0 | |||
| Aggregate Net Value ($) | 0 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| DAVIS HUGH M. | Officer | 02 Dec 2025 | Option execute | 26,750 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |